Ajinomoto Co., Inc. has signed a licensing agreement with Astellas Pharma Inc. for the use of AJICAP—an antibody-drug conjugate (ADC) development and manufacturing technology—as part of its CDMO ...

To reach the target audience of geographic atrophy (GA) treatment Izervay, Astellas Pharma has turned to the “internet’s ...

(Reuters) -Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor recurrence, progression or death in patients suffering from a type of bladder ...

Pfizer Inc. (NYSE:PFE) is one of the Most Undervalued Long Term Stocks to Buy Right Now. On October 19, Pfizer Inc. (NYSE:PFE ...

Pharma titans Merck, Pfizer and Astellas Pharma are delivering an "enormous new hope" for patients with an aggressive form of ...

Astellas is continuing to strengthen its neurological disease gene therapy capabilities, handing Sangamo Therapeutics $20 million upfront to help bypass the blood-brain barrier (BBB). The agreement ...

The "Bladder Cancer Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.The market's growth is primarily driven by the rising ...

Bayer’s Lynkuet, approved for treating moderate-to-severe vasomotor symptoms of menopause, targets two receptors key to ...

Astellas entered gene therapy development via a $3 billion acquisition. Another deal now positions it to potentially expand its gene therapy franchise further. Astellas is taking a minority stake in ...

Astellas is spinning up a new attack on a cancer market, paying $175 million to buy Propella Therapeutics and its clinical-phase challenger to Johnson & Johnson’s fast-fading prostate cancer ...

Kenji Yasukawa, Ph.D., the new Astellas CEO, pledged to push the Japanese drugmaker further into gene and cell therapies for ocular, oncology and other diseases. Now the company says it will invest ...

Astellas has become the latest big pharma company to sink some money into immuno-oncology start-up GO Therapeutics, forging an alliance to develop antibodies targeting two glycoprotein targets. The ...